S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Cameco Stock is the Real Deal Uranium Play
pixel
3 Overdone Selloffs Offering a Second Chance
3 Value Stocks in Focus as Rotation Continues
2 Undervalued Consumer Stocks For Your Watchlist
pixel
Kroger Stock Presents Investors With a Crisis of Conviction
Shares slip in Asia after bond yield spike hits Wall St
Reading International Stock is an Under the Radar Dual Reopening Play
pixel
Log in
NASDAQ:ATNF

180 Life Sciences Stock Forecast, Price & News

$4.03
+0.09 (+2.28 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.51
Now: $4.03▼
$4.11
50-Day Range
$3.09
MA: $4.53▼
$6.72
52-Week Range
$1.90
Now: $4.03▼
$11.50
Volume750,055 shs
Average Volume1.71 million shs
Market Capitalization$72.67 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.55
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.

Headlines

180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement
February 24, 2021 |  finance.yahoo.com
180 Life Sciences Corp. Announces $11.7 Million Private Placement
February 19, 2021 |  finance.yahoo.com
Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)?
February 17, 2021 |  finance.yahoo.com
The #1 Danger Sign You're Drinking Too Much Coffee, According to Science
January 12, 2021 |  msn.com
180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference
January 11, 2021 |  finance.yahoo.com
US Capitol attack: Trump impeachment looms as Republicans ponder his fate
January 9, 2021 |  msn.com
Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain
January 7, 2021 |  prnewswire.com
180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference
January 5, 2021 |  finance.yahoo.com
180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST
December 3, 2020 |  finance.yahoo.com
180 Life Sciences Corp. Rings the Opening Bell
November 27, 2020 |  nasdaq.com
180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020
November 24, 2020 |  finance.yahoo.com
180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants
November 23, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.kblmerger.com
Phone302-502-2727
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio0.18
Quick Ratio0.18

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.12 per share
Price / Book3.60

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-90,000.00
Net MarginsN/A
Return on Equity-94.05%
Return on Assets-38.77%

Miscellaneous

Outstanding Shares18,032,000
Market Cap$72.67 million
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.33 out of 5 stars

Medical Sector

1751st out of 1,972 stocks

Pharmaceutical Preparations Industry

715th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$4.03
+0.09 (+2.28 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATNF News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











180 Life Sciences (NASDAQ:ATNF) Frequently Asked Questions

What stocks does MarketBeat like better than 180 Life Sciences?

Wall Street analysts have given 180 Life Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 180 Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting 180 Life Sciences?

180 Life Sciences saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 461,200 shares, an increase of 54.6% from the January 28th total of 298,300 shares. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is currently 0.3 days. Currently, 17.0% of the shares of the stock are short sold.
View 180 Life Sciences' Short Interest.

When is 180 Life Sciences' next earnings date?

180 Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for 180 Life Sciences.

Who are 180 Life Sciences' key executives?

180 Life Sciences' management team includes the following people:
  • Prof. Marc Feldmann, Exec. Co-Chairman
  • Dr. Lawrence Steinman, Exec. Co-Chairman (Age 73)
  • Dr. James N. Woody, Chief Exec. Officer (Age 79)
  • Mr. Ozan Pamir, Chief Financial Officer (Age 30)
  • Dr. Jonathan B. Rothbard, Chief Scientific Officer
  • Prof. Jagdeep Nanchahal, Chief Medical Officer

Who are some of 180 Life Sciences' key competitors?

Some companies that are related to 180 Life Sciences include Arbutus Biopharma (ABUS), Galera Therapeutics (GRTX), Ampio Pharmaceuticals (AMPE), Kamada (KMDA), Nabriva Therapeutics (NBRV), Kezar Life Sciences (KZR), MediciNova (MNOV), Hookipa Pharma (HOOK), Larimar Therapeutics (LRMR), Lannett (LCI), Sernova (SEOVF), Ovid Therapeutics (OVID), Theratechnologies (THERF), Tricida (TCDA) and Xeris Pharmaceuticals (XERS).
View all of ATNF's competitors.

What is 180 Life Sciences' stock symbol?

180 Life Sciences trades on the NASDAQ under the ticker symbol "ATNF."

How do I buy shares of 180 Life Sciences?

Shares of ATNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 180 Life Sciences' stock price today?

One share of ATNF stock can currently be purchased for approximately $4.03.

How much money does 180 Life Sciences make?

180 Life Sciences has a market capitalization of $72.67 million.

What is 180 Life Sciences' official website?

The official website for 180 Life Sciences is www.kblmerger.com.

Where are 180 Life Sciences' headquarters?

180 Life Sciences is headquartered at 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007.

How can I contact 180 Life Sciences?

180 Life Sciences' mailing address is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. The company can be reached via phone at 302-502-2727 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.